Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent–Naive Subjects with Type 2 Diabetes
Authors:
- 1 June 2013
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 15 (6) , 481-488
Abstract
Background: Recent studies have identified postprandial glycemic excursions as risk factors for diabetes complications. This study aimed to compare the effects of nateglinide and acarbose treatments on postprandial glycemic excursions in Chinese subjects with type 2 diabetes. Subjects and Methods: This was a multicenter, open-label, randomized, active-controlled, parallel-group study. One hundred three antihyperglycemic agent–naive subjects with type 2 diabetes (hemoglobin A1c range, 6.5–9.0%) were prospectively recruited from four hospitals in China. The intervention was nateglinide (120 mg three times a day) or acarbose (50 mg three times a day) therapy for 2 weeks. A continuous glucose monitoring system was used to calculate the incremental area under the curve of postprandial blood glucose (AUC pp ), the incremental glucose peak (IGP), mean amplitude of glycemic excursions, SD of blood glucose, the mean of daily differences, and 24-h mean blood glucose (MBG). Subjects' serum glycated albumin and the plasma insulin levels were also analyzed. Results: Both agents caused significant reductions on AUC pp and IGP. Similarly, both treatment groups showed significant improvements in the intra- and interday glycemic excursions, as well as the 24-h MBG and serum glycated albumin compared with baseline ( P 0.05). Moreover, the nateglinide-treated group had significantly increased insulin levels at 30 min and at 120 min after a standard meal compared with baseline, whereas the acarbose-treated group decreased. No serious adverse events occurred in either group. The rates of hypoglycemic episodes were comparable in the two groups, and no severe hypoglycemic episode occurred in either group. Conclusions: Nateglinide and acarbose were comparably effective in reducing postprandial glycemic excursions in antihyperglycemic agent–naive Chinese patients with type 2 diabetes, possibly through different pathophysiological mechanisms.Keywords
This publication has 31 references indexed in Scilit:
- The glucose triad and its role in comprehensive glycaemic control: current status, future managementInternational Journal Of Clinical Practice, 2010
- Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular EventsNew England Journal of Medicine, 2010
- Prevalence of Diabetes among Men and Women in ChinaNew England Journal of Medicine, 2010
- Improvement of insulin sensitivity and β‐cell function by nateglinide and repaglinide in type 2 diabetic patients – a randomized controlled double‐blind and double‐dummy multicentre clinical trialDiabetes, Obesity and Metabolism, 2006
- Glycaemic instability is an underestimated problem in Type II diabetesClinical Science, 2006
- Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?European Journal of Clinical Investigation, 2000
- Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?European Journal of Clinical Investigation, 2000
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJournal of Clinical Investigation, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Abnormal Patterns of Insulin Secretion in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988